Result

Search results for the GEO ID: GSE43124

(Click on the check boxes provided under "Select for analysis", to initiate grouping)

(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down)

GSM ID

GPL ID

Select for analysis

Title

Source name

Description

Characteristics

GSM1057002

GPL570

DoVeD-1

CD34+ cells from patients post-DoVeD therapy

disease state: multiple myeloma treatment: bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 3722 Amplified RNA.

Sample_geo_accession	GSM1057002
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057002/suppl/GSM1057002_7207.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057003

GPL570

DoVeD-2

CD34+ cells from patients post-DoVeD therapy

disease state: multiple myeloma treatment: bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 3469 Amplified RNA.

Sample_geo_accession	GSM1057003
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057003/suppl/GSM1057003_7208.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057004

GPL570

DoVeD-3

CD34+ cells from patients post-DoVeD therapy

disease state: multiple myeloma treatment: bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 3728 Amplified RNA.

Sample_geo_accession	GSM1057004
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057004/suppl/GSM1057004_7209.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057005

GPL570

DoVeD-4

CD34+ cells from patients post-DoVeD therapy

disease state: multiple myeloma treatment: bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 4015 Amplified RNA.

Sample_geo_accession	GSM1057005
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057005/suppl/GSM1057005_7210.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057006

GPL570

DoVeD-5

CD34+ cells from patients post-DoVeD therapy

disease state: multiple myeloma treatment: bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 4370 Amplified RNA.

Sample_geo_accession	GSM1057006
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057006/suppl/GSM1057006_7211.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057007

GPL570

filgrastim + cyclophosphamide-1

CD34+ cells from patients post-G-CSF+Cytoxan therapy

disease state: multiple myeloma treatment: non-bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 3924 Amplified RNA.

Sample_geo_accession	GSM1057007
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057007/suppl/GSM1057007_7367.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057008

GPL570

filgrastim + cyclophosphamide-2

CD34+ cells from patients post-G-CSF+Cytoxan therapy

disease state: multiple myeloma treatment: non-bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 3779 Amplified RNA.

Sample_geo_accession	GSM1057008
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057008/suppl/GSM1057008_7368.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

GSM1057009

GPL570

filgrastim + cyclophosphamide-3

CD34+ cells from patients post-G-CSF+Cytoxan therapy

disease state: multiple myeloma treatment: non-bortezomib-based mobilization tissue: blood (leukapheresis products) cell type: CD34+ stem cells

PB 3334 Amplified RNA.

Sample_geo_accession	GSM1057009
Sample_status	Public on Feb 13 2013
Sample_submission_date	Dec 21 2012
Sample_last_update_date	Feb 13 2013
Sample_type	RNA
Sample_channel_count	1
Sample_organism_ch1	Homo sapiens
Sample_taxid_ch1	9606
Sample_treatment_protocol_ch1	DoVeD induction: bortezomib-dexamethasone ± liposomal doxorubicin. Non-bortezomib induction: filgrastim + cyclophosphamide.
Sample_growth_protocol_ch1	N/A
Sample_molecule_ch1	total RNA
Sample_extract_protocol_ch1	RNeasy micro kit (Qiagen, Valencia, CA).
Sample_label_ch1	Biotin
Sample_label_protocol_ch1	25-250 ng of total RNA were reverse transcribed and amplified using the WT-Ovation Pico RNA amplification system (NuGEN Technologies, San Carlos, CA). 5 ug of amplified cDNA were fragmented and labeled with biotin using the FL-Ovation CDNA Biotin Module (Nugen Technologies, San Carlos, CA) version 2.
Sample_hyb_protocol	Following fragmentation and labeling, 5 ug of labeled cDNA were hybridized for 16 hr at 45 degrees Celsius on the Affymetrix HG-U133 Plus 2.0 microarray chips (Affymetrix). GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
Sample_scan_protocol = GeneChips were scanned using the Affymetrix GeneChip scanner (GCS); Scanner type	M10.
Sample_data_processing	GC-RMA normalization and baseline transformation were performed using GeneSpring 12.1 (Agilent Technologies and Strand Life Science) using default parameters. Data were analyzed in GeneSpring 12.1 using the following parameters: Filtered on expression (50), corrected p-value cutoff of 0.05, unpaired T-test between the 2 mobilization groups, p-value computation was asymptotic and Benjamini-Hochberg multiple test correction was applied. Differential expression between the DoVed and filgrastim + cyclophosphamide groups was further analyzed using a greater than 2.0-fold change in gene regulation.
Sample_platform_id	GPL570
Sample_contact_name	Maureen,E,Lane
Sample_contact_email	mel2009@med.cornell.edu
Sample_contact_laboratory	Lane
Sample_contact_department	Medicine
Sample_contact_institute	Weill Cornell Medical College
Sample_contact_address	1300 York Avenue
Sample_contact_city	New York
Sample_contact_state	NY
Sample_contact_zip/postal_code	10065
Sample_contact_country	USA
Sample_supplementary_file	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM1057nnn/GSM1057009/suppl/GSM1057009_7369.CEL.gz
Sample_series_id	GSE43124
Sample_data_row_count	54675

Make groups for comparisons

(2 groups will be compared at a time)

Select GSMs and click on "Add groups"

Enter the group name here:

Select expression type

Transcripts profile based on;

A. Differential status (Up/Down regulation)

B. Absolute calls (Transcribed/Not-detected)

Filter results by number of probes